Jason Trubiano
Prof/Director of Infectious Diseases & Immunology @austin_health. UoM Research Fellow @ID_austin @CAAR_Aus @TheDohertyInst @UniMelbMDHS #AMS #AMR #penicillinallergy #drugallergy #TID
- 💊Drug Hypesensitivity Symposium 2026 - #DHS2026 Registrations are now open for our amazing 3-day #drugallergy & #antibioticallergy program in Melbourne 23-25th October 2026. Stellar international🌏speaker lineup. @allergy-eaaci.bsky.social @thedohertyinst.bsky.social ➡️https://dhs2026.org/
- The largest adult #penicillinallergy study ever undertaken - The iNAAN study @thedohertyinst.bsky.social @unimelb.bsky.social - 52 hospitals, 8 countries and over 5000 patients….Real world proof of the safety and effectiveness of inpatient DOC! Stay tuned #AMS folks 👀Results soon!
- Is one dose ever enough? The PROSPECTOR 🪓 Trial will answer - A international double blind placebo controlled trial of 1 dose vs 5 day for #penicillinallergy. This week we recruited our 100th patient! 🎉 @thedohertyinst.bsky.social
- Reposted by Jason TrubianoIn high-income countries, up to 11.5% of adults report a penicillin allergy, and in high-risk groups prevalence can reach 35%. However, more than 90% of these labels are inaccurate, resulting in substantial clinical and public health consequences in hospitals and communities #idsky
- 🆕🔥State-of-the-Art Review with 🌟s @trubianojason.bsky.social : Antibiotic Allergy—A Multidisciplinary Approach to Delabeling #idsky url: academic.oup.com/cid/article/...
- Reposted by Jason Trubiano🆕🔥State-of-the-Art Review with 🌟s @trubianojason.bsky.social : Antibiotic Allergy—A Multidisciplinary Approach to Delabeling #idsky url: academic.oup.com/cid/article/...
- Congratulations Elise Mitri from NACE, Austin Health & The Peter Doherty Institute presenting the iNAAN Trial results - > 5000 pts & 1500 inpatient #penicillinallergy DOC performed. Safe irrespective of stakeholder with significant prescribing gains. Largest inpatient penicillin allergy study 👏🎉
- Is one dose enough?! Great talk from Dr Rose for the #PROSPECTOR #penicillinallergy #RCT at #EAACI HK Summer School. 6.7% increase in immune mediated reactions with prolonged oral challenge. Looking forward to #PROSPECTOR2 definitive phase III study to change practice!
- Excited to be at EAACI Hong Kong School 2025 Hosted by Prof Li. Can’t wait for Elise Mitri from The Peter Doherty Institute to present the #iNAAN Results - #PenicillinAllergy #delabing Global Implementation! Dr Rose will present #PROSPECTOR1 - is one dose enough to delabel penicillin allergy?!? ‼️👀
- Thank you @eurekaprizes.bsky.social for the opportunity and my research team Austin Health & Doherty Institute for driving the research in #antibioticallergy #EurekaPrizes
- Professor @trubianojason.bsky.social is a finalist in the Eureka Prize for Emerging Leader in Science. Learn more: youtu.be/qaPw-YsXix4 #EurekaPrizes
- #ESCMIDGlobal #FOMO…. Watching online the amazing @elisemitri.bsky.social and thanks to @cmicomms.bsky.social for publishing this work! Not missing another #ESCMIDGlobal!!
- Congrats to @elisemitri.bsky.social, @trubianojason.bsky.social et al for their great work on safely delabeling patients with #penicillinallergy. Elise presenting their prospective, pharmacist-led program live at #ESCMIDGlobal #IDSky #PharmSky #openacess www.cmi-comms.com/article/S295...
- Hopefully can get a # going for the conference - #ASID2025 ? Get some of the proffered papers and new research out from #EMCR #IDResearch #Infectiousdiseases
- Reposted by Jason TrubianoASID Annual Scientific Meeting kicked off yesterday in Canberra. The pre-conference workshop hosted by Therapeutic Guidelines Australia attracted over 120 attendees and was a very engaging and informative session. The formal program commences tomorrow in what will be one of the largest ASM’s.
- Well done team 👏 Perioperative Penicillin and Cephalosporin Antibiotic Allergy Assessment and Testing: The PREPARE Randomized Clinical Trial jamanetwork.com/journals/jam...
- We randomised our first patients yesterday into the #PROSPECTOR2 ⛏️ study - international superioty trail of 1 dose versus day challenge for #penicillinallergy. “Is one dose ever enough….”
- www.sciencedirect.com/science/arti... - nice review and global prevalence number!
- Reposted by Jason TrubianoVery proud of this hard work & team effort from all involved! Limited benefit of adjuvanted flu 💉 & 2 vs 1 dose in pts w/ MM, CLL or NHL. @ncicancer.bsky.social @petermaccc.bsky.social @benwteh.bsky.social @trubianojason.bsky.social @michyong.bsky.social @nejm.org www.nejm.org/doi/full/10....
- Reposted by Jason Trubiano📣 @elisemitri.bsky.social et al prospectively assessed 477 inpatients with #penicillin allergy. 166 were low-risk & underwent oral challenge: 158 (95%) delabeled. 111 (type A allergy) delabeled without challenge. ➡️ No SAE #IDSky #MedSky @trubianojason.bsky.social www.cmi-comms.com/article/S295...
- Reposted by Jason Trubiano🆕💫Prospective cohort study The long-term sustainability of a pharmacist-led antimicrobial stewardship penicillin allergy delabelling ward round with 🌟 @trubianojason.bsky.social @cmicomms.bsky.social #idsky www.sciencedirect.com/science/arti...
- 1000 direct oral #penicillinallergy challenges in the prospective iNAAN study 🎉- 39 hospitals and 7 countries 😳. The largest adult penicillin challenge study! Well done @elisemitri.bsky.social 👏👏 and all collaborators! @escmid.bsky.social data coming hopefully to #ESCMIDglobal 2025!
- Reposted by Jason Trubiano🚨 Delighted to share our paper defining a new role for IL-6 in TB. 🚨 We used genetic variation to show *reduced* IL-6 signalling is causally associated with *lower* risk of TB. Lead author @gushamilton.bsky.social #TBSky #IDSky #ImmunoSky www.thelancet.com/journals/lan... Thread 👇 (1/8)
- Reposted by Jason TrubianoThe incredibly impressive Ouli Xie is presenting his PhD completion seminar on Monday Nov 25 at 12.30pm AEDT. "The clinical, epidemiological, and evolutionary intersection between Streptococcus dysgalactiae subspecies equisimilis and Streptococcus pyogenes" unimelb.zoom.us/j/8944229688...?
- Reposted by Jason TrubianoFeels right that my 1st post here should be to share this incredible RCT, led by my PhD supervisor Nick Daneman: www.nejm.org/doi/full/10.... Main takeaway: 7-days of abx should be the standard of care for patients with uncomplicated non-S. aureus BSI. A deep dive 🧵: #IDsky
- Reposted by Jason TrubianoHi #IDSky! I’m putting together my usual top 10 ID papers of this year list again (this time will post here not in the other world). Please tell me your candidate papers - practice changing paradigm shifting or dogma challenging!
- Thought worth a share on #WAAW @ncas.bsky.social day today. A practical guide to #penicillinallergy into inpatient #AMS programs. A partner to implementation! #IDSky #MedSky pubmed.ncbi.nlm.nih.gov/39444148/
- #WAAW kicking off at @ncas.bsky.social symposium today 🇦🇺. Looking forward to a great program and a lot of representation from team #AustinHealth #AMS #DrugAllergy
- Reposted by Jason TrubianoIt's World Antimicrobial Resistance Awareness Week! #WAAW NCAS are proud to join the global community in highlighting the importance of #AMS education, research and training across One Health 🧑🤝🧑🐕🦺🌴 #IDSky #AMSSky
- #PROSPECTOR1 ⛏️double blind pilot feasibility RCT of single dose vs. multi dose challenge for #penicillinallergy fully recruited! Can’t wait for the results… and PROSPECTOR2 to commence internationally in 2025! Stay tuned… #IDSky #MedSky #AISky
- Reposted by Jason Trubiano
- #Forbes2024 - From risk assessment to vaccination - Pearls of Wisdom from @kottonnelson.bsky.social on #TID role pre transplant. Lots of learnings from our Forbes Fellow #ASID #IDsky
- Reposted by Jason TrubianoGood morning #IDSky. Here's one that's more than a decade old, though I still remember the conversation like it was yesterday. 😆 blogs.jwatch.org/hiv-id-obser...
